Intrinsic value of FibroGen - FGEN

Previous Close

$65.05

  Intrinsic Value

$2.28

stock screener

  Rating & Target

str. sell

-97%

Previous close

$65.05

 
Intrinsic value

$2.28

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of FGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 4.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  129
  131
  135
  139
  143
  147
  152
  158
  164
  170
  177
  184
  192
  200
  208
  217
  227
  237
  248
  260
  272
  284
  298
  312
  327
  342
  359
  376
  394
  413
Variable operating expenses, $m
  167
  171
  175
  180
  185
  191
  198
  205
  212
  221
  229
  239
  249
  259
  270
  282
  295
  308
  322
  337
  352
  369
  386
  404
  424
  444
  465
  488
  511
  536
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  167
  171
  175
  180
  185
  191
  198
  205
  212
  221
  229
  239
  249
  259
  270
  282
  295
  308
  322
  337
  352
  369
  386
  404
  424
  444
  465
  488
  511
  536
Operating income, $m
  -38
  -39
  -40
  -41
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -59
  -62
  -65
  -67
  -70
  -74
  -77
  -81
  -84
  -88
  -93
  -97
  -102
  -107
  -112
  -117
  -123
EBITDA, $m
  -25
  -26
  -26
  -27
  -28
  -29
  -30
  -31
  -32
  -33
  -35
  -36
  -38
  -39
  -41
  -43
  -45
  -47
  -49
  -51
  -53
  -56
  -58
  -61
  -64
  -67
  -70
  -74
  -77
  -81
Interest expense (income), $m
  0
  10
  -2
  -1
  -1
  0
  1
  2
  2
  3
  4
  5
  7
  8
  9
  10
  12
  13
  15
  17
  19
  21
  23
  25
  27
  30
  32
  35
  38
  40
  44
Earnings before tax, $m
  -48
  -37
  -39
  -41
  -42
  -45
  -47
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -77
  -81
  -86
  -91
  -96
  -101
  -107
  -113
  -120
  -127
  -134
  -141
  -149
  -158
  -166
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -48
  -37
  -39
  -41
  -42
  -45
  -47
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -77
  -81
  -86
  -91
  -96
  -101
  -107
  -113
  -120
  -127
  -134
  -141
  -149
  -158
  -166

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  246
  251
  258
  265
  273
  282
  292
  302
  313
  325
  338
  352
  366
  382
  398
  416
  434
  454
  474
  496
  519
  544
  569
  596
  624
  654
  686
  719
  754
  790
Adjusted assets (=assets-cash), $m
  246
  251
  258
  265
  273
  282
  292
  302
  313
  325
  338
  352
  366
  382
  398
  416
  434
  454
  474
  496
  519
  544
  569
  596
  624
  654
  686
  719
  754
  790
Revenue / Adjusted assets
  0.524
  0.522
  0.523
  0.525
  0.524
  0.521
  0.521
  0.523
  0.524
  0.523
  0.524
  0.523
  0.525
  0.524
  0.523
  0.522
  0.523
  0.522
  0.523
  0.524
  0.524
  0.522
  0.524
  0.523
  0.524
  0.523
  0.523
  0.523
  0.523
  0.523
Average production assets, $m
  129
  132
  136
  140
  144
  148
  154
  159
  165
  171
  178
  185
  193
  201
  210
  219
  229
  239
  250
  261
  273
  286
  300
  314
  329
  345
  361
  379
  397
  416
Working capital, $m
  -6
  -6
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
  -10
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -14
  -15
  -16
  -17
  -17
  -18
Total debt, $m
  -17
  -12
  -6
  1
  8
  16
  25
  34
  44
  55
  66
  79
  92
  106
  121
  136
  153
  171
  189
  209
  229
  251
  274
  299
  324
  351
  379
  409
  440
  473
Total liabilities, $m
  221
  226
  232
  239
  246
  254
  262
  272
  282
  293
  304
  317
  330
  344
  359
  374
  391
  408
  427
  447
  467
  489
  512
  536
  562
  589
  617
  647
  678
  711
Total equity, $m
  25
  25
  26
  27
  27
  28
  29
  30
  31
  33
  34
  35
  37
  38
  40
  42
  43
  45
  47
  50
  52
  54
  57
  60
  62
  65
  69
  72
  75
  79
Total liabilities and equity, $m
  246
  251
  258
  266
  273
  282
  291
  302
  313
  326
  338
  352
  367
  382
  399
  416
  434
  453
  474
  497
  519
  543
  569
  596
  624
  654
  686
  719
  753
  790
Debt-to-equity ratio
  -0.680
  -0.460
  -0.230
  0.030
  0.290
  0.560
  0.840
  1.120
  1.400
  1.680
  1.960
  2.240
  2.510
  2.770
  3.030
  3.280
  3.520
  3.760
  3.990
  4.210
  4.420
  4.620
  4.820
  5.010
  5.190
  5.360
  5.530
  5.690
  5.840
  5.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -48
  -37
  -39
  -41
  -42
  -45
  -47
  -49
  -52
  -55
  -58
  -61
  -65
  -68
  -72
  -77
  -81
  -86
  -91
  -96
  -101
  -107
  -113
  -120
  -127
  -134
  -141
  -149
  -158
  -166
Depreciation, amort., depletion, $m
  13
  13
  14
  14
  14
  15
  15
  16
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
  36
  38
  40
  42
Funds from operations, $m
  -35
  -24
  -25
  -27
  -28
  -30
  -32
  -33
  -36
  -38
  -40
  -43
  -45
  -48
  -51
  -55
  -58
  -62
  -66
  -70
  -74
  -79
  -83
  -88
  -94
  -99
  -105
  -111
  -118
  -125
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from operations, $m
  -35
  -24
  -25
  -26
  -28
  -30
  -31
  -33
  -35
  -37
  -40
  -42
  -45
  -48
  -51
  -54
  -58
  -61
  -65
  -69
  -73
  -78
  -83
  -88
  -93
  -99
  -104
  -111
  -117
  -124
Maintenance CAPEX, $m
  -13
  -13
  -13
  -14
  -14
  -14
  -15
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -36
  -38
  -40
New CAPEX, $m
  -3
  -3
  -3
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -17
  -18
  -19
Cash from investing activities, $m
  -16
  -16
  -16
  -18
  -18
  -19
  -20
  -20
  -22
  -22
  -24
  -25
  -27
  -27
  -29
  -30
  -32
  -33
  -35
  -36
  -38
  -40
  -42
  -44
  -46
  -49
  -51
  -53
  -56
  -59
Free cash flow, $m
  -50
  -40
  -42
  -44
  -46
  -49
  -51
  -54
  -57
  -60
  -64
  -67
  -71
  -75
  -80
  -84
  -89
  -94
  -100
  -106
  -112
  -118
  -125
  -132
  -139
  -147
  -155
  -164
  -173
  -183
Issuance/(repayment) of debt, $m
  -114
  5
  6
  7
  7
  8
  9
  9
  10
  11
  12
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  22
  23
  24
  26
  27
  28
  30
  31
  33
Issuance/(repurchase) of shares, $m
  168
  38
  40
  41
  43
  45
  48
  50
  53
  56
  59
  63
  66
  70
  74
  78
  83
  88
  93
  98
  104
  110
  116
  122
  129
  137
  144
  153
  161
  170
Cash from financing (excl. dividends), $m  
  54
  43
  46
  48
  50
  53
  57
  59
  63
  67
  71
  75
  79
  84
  89
  94
  100
  106
  112
  118
  125
  132
  139
  146
  155
  164
  172
  183
  192
  203
Total cash flow (excl. dividends), $m
  4
  3
  4
  4
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  13
  13
  14
  15
  16
  16
  17
  18
  19
  20
Retained Cash Flow (-), $m
  -168
  -38
  -40
  -41
  -43
  -45
  -48
  -50
  -53
  -56
  -59
  -63
  -66
  -70
  -74
  -78
  -83
  -88
  -93
  -98
  -104
  -110
  -116
  -122
  -129
  -137
  -144
  -153
  -161
  -170
Prev. year cash balance distribution, $m
  658
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  32
  32
  33
  34
  35
  36
  37
  38
  39
  41
  43
  44
  46
  48
  50
  52
  54
  57
  59
  62
  65
  68
  71
  74
  78
  82
  86
  90
  94
  99
Cash available for distribution, $m
  494
  -35
  -36
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -52
  -55
  -58
  -61
  -65
  -69
  -73
  -77
  -81
  -86
  -91
  -96
  -102
  -108
  -114
  -120
  -127
  -134
  -142
  -150
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  473
  -32
  -31
  -31
  -30
  -29
  -29
  -28
  -27
  -26
  -25
  -23
  -22
  -21
  -19
  -17
  -16
  -14
  -13
  -11
  -9
  -8
  -7
  -5
  -4
  -4
  -3
  -2
  -2
  -1
Current shareholders' claim on cash, %
  50.0
  42.3
  35.6
  29.9
  25.1
  20.9
  17.4
  14.5
  12.0
  9.9
  8.1
  6.7
  5.4
  4.4
  3.6
  2.9
  2.4
  1.9
  1.5
  1.2
  1.0
  0.8
  0.6
  0.5
  0.4
  0.3
  0.3
  0.2
  0.2
  0.1

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

FINANCIAL RATIOS  of  FibroGen (FGEN)

Valuation Ratios
P/E Ratio -66.8
Price to Sales 23
Price to Book 26.5
Price to Tangible Book
Price to Cash Flow 591.6
Price to Free Cash Flow 690.2
Growth Rates
Sales Growth Rate -0.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate -32.2%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 71.8%
Total Debt to Equity 71.8%
Interest Coverage 0
Management Effectiveness
Return On Assets -13.2%
Ret/ On Assets - 3 Yr. Avg. -15.5%
Return On Total Capital -22.2%
Ret/ On T. Cap. - 3 Yr. Avg. -24.1%
Return On Equity -37.1%
Return On Equity - 3 Yr. Avg. -40%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -31.1%
EBITDA Margin - 3 Yr. Avg. -38.6%
Operating Margin -29.4%
Oper. Margin - 3 Yr. Avg. -36.1%
Pre-Tax Margin -34.4%
Pre-Tax Margin - 3 Yr. Avg. -41.8%
Net Profit Margin -34.4%
Net Profit Margin - 3 Yr. Avg. -41.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

FGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the FGEN stock intrinsic value calculation we used $126 million for the last fiscal year's total revenue generated by FibroGen. The default revenue input number comes from 2017 income statement of FibroGen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our FGEN stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for FGEN is calculated based on our internal credit rating of FibroGen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of FibroGen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of FGEN stock the variable cost ratio is equal to 129.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for FGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for FibroGen.

Corporate tax rate of 27% is the nominal tax rate for FibroGen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the FGEN stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for FGEN are equal to 100.7%.

Life of production assets of 10 years is the average useful life of capital assets used in FibroGen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for FGEN is equal to -4.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $563 million for FibroGen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 73 million for FibroGen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of FibroGen at the current share price and the inputted number of shares is $4.7 billion.

RELATED COMPANIES Price Int.Val. Rating
AKBA Akebia Therape 10.29 0.68  str.sell
BMY Bristol-Myers 56.71 54.20  hold
AZN AstraZeneca AD 37.17 55.39  str.buy
ARDX Ardelyx 4.40 0.74  str.sell
PTCT PTC Therapeuti 39.98 687.26  str.buy
ABBV AbbVie 88.91 93.18  hold
PFE Pfizer 37.33 24.58  sell

COMPANY NEWS

▶ FibroGen to Present at Two Upcoming Investor Conferences   [Jun-04-18 02:05PM  GlobeNewswire]
▶ FibroGen: 1Q Earnings Snapshot   [May-09-18 05:31PM  Associated Press]
▶ FibroGen reports 4Q loss   [Feb-28-18 05:04AM  Associated Press]
▶ FibroGen, Inc. to Host Earnings Call   [01:30PM  ACCESSWIRE]
▶ FibroGen Q4 Earnings Outlook   [12:53PM  Benzinga]
▶ ETFs with exposure to FibroGen, Inc. : December 27, 2017   [Dec-27-17 11:15AM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : December 15, 2017   [Dec-15-17 01:21PM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : November 20, 2017   [Nov-20-17 12:27PM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : November 8, 2017   [Nov-08-17 06:07PM  Capital Cube]
▶ FibroGen reports 3Q loss   [05:31PM  Associated Press]
▶ FibroGen, Inc. to Host Earnings Call   [02:10PM  ACCESSWIRE]
▶ Is It Too Late To Buy FibroGen Inc (FGEN)?   [07:29AM  Simply Wall St.]
▶ ETFs with exposure to FibroGen, Inc. : October 24, 2017   [Oct-24-17 09:38AM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : October 13, 2017   [Oct-13-17 10:47AM  Capital Cube]
▶ Cramer's lightning round: Let Nike walk these losses off   [Oct-10-17 07:04PM  CNBC Videos]
▶ 3 Under-the-Radar Small Cap Gems   [Oct-02-17 11:14AM  Investopedia]
▶ FibroGen Inc (FGEN): How Does It Impact Your Portfolio?   [Sep-30-17 07:17AM  Simply Wall St.]
▶ FibroGen Appoints Gerald Lema to Board of Directors   [Sep-19-17 04:35PM  GlobeNewswire]
▶ Why This Cancer Biotech Leads Pack After Hitting Record High   [Sep-13-17 04:33PM  Investor's Business Daily]
▶ Is There Now An Opportunity In FibroGen Inc (FGEN)?   [Sep-06-17 07:14PM  Simply Wall St.]
▶ Why Ralph Lauren, LendingClub, and FibroGen Jumped Today   [Aug-08-17 04:20PM  Motley Fool]
▶ Why FibroGen Inc Skyrocketed Higher Today   [02:37PM  Motley Fool]
▶ Why Fibrogen Shares Are Exploding   [10:55AM  24/7 Wall St.]
▶ FibroGen reports 2Q loss   [Aug-07-17 11:00PM  Associated Press]
▶ ETFs with exposure to FibroGen, Inc. : June 2, 2017   [Jun-02-17 02:07PM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : May 22, 2017   [May-22-17 01:39PM  Capital Cube]
▶ FibroGen Reports First Quarter 2017 Financial Results   [May-09-17 04:02PM  GlobeNewswire]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.